Awinita Barpujari

Ms. Awinita Barpujari

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2022 in World Neurosurgery
Verified
Journal Article
Closed access
AGArjun Gupta
Arjun Gupta
VRVamsi Reddy
Vamsi Reddy
ABAwinita Barpujari
Awinita Barpujari
RLRaj Swaroop Lavadi
Raj Swaroop Lavadi
PAPrateek Agarwal
Prateek Agarwal
NANitin Agarwal
Nitin Agarwal

13 April 2022 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
ABAwinita Barpujari
Awinita Barpujari
MMMehul Mehra
Mehul Mehra
RSRohin Singh
Rohin Singh
KWKendra Wang
Kendra Wang
BSBenjamin Sherman
Benjamin Sherman
DHDavid B. Hoyt
David B. Hoyt
As health care and politics have become increasingly intertwined, government policy has directly impacted the access, delivery, and compensation of health care services.1-3 However, less considered is the influence of individual physicians on the formation and enactment of legislation. Blurring the distinction between personal and professional views, physicians’ ideologies are often a balance between the health care of patients and their own personal wealth. Individual political affiliation is publicized now more than ever, and it is imperative to analyze how physicians’ political attitudes influence partisan legislation.

29 November 2023 in World Neurosurgery
Verified
Journal Article
Closed access
SPSangami Pugazenthi
Sangami Pugazenthi
ABAwinita Barpujari
Awinita Barpujari
SPSaarang Patel
Saarang Patel
EEEmily M. Estes
Emily M. Estes
VRVamsi Reddy
Vamsi Reddy
JSJennifer M. Strahle
Jennifer M. Strahle

22 December 2020 in Pain Management
Verified
Journal Article
Closed access
ABAwinita Barpujari
Awinita Barpujari
MEMichael Erdek
Michael Erdek
Aim: Spinal cord stimulation (SCS) is used to clinically manage and/or treat several chronic pain etiologies. A limited amount is known about the influence on patients' use of opioid pain medicatio...

3 August 2021 in Pain
Verified
Journal Article
Closed access
SSStefani M. Schwartz
Stefani M. Schwartz
ABAwinita Barpujari
Awinita Barpujari
NFNanna Brix Finnerup
Nanna Brix Finnerup
SRSrinivasa N. Mbbs Raja
Srinivasa N. Mbbs Raja
Several different reporting biases cited in scientific literature have raised concerns about the overestimation of effects and the subsequent potential impact on the practice of evidence-based medicine and human health. Up to 7% to 8% of the population experiences neuropathic pain (NP), and established treatment guidelines are based predominantly on published clinical trial results. Therefore, we examined published randomized controlled trials (RCTs) of first-line drugs for NP and assessed the relative proportions with statistically significant (ie, positive) and nonsignificant (ie, negative) results and their rates of citation. We determined the relationships between reported study outcome and the frequency of their citations with journal impact factor, sample size, time to publication after study completion, and study quality metrics. We also examined the association of study outcome with maximum study drug dosage and conflict of interest. We found that of 107 published RCTs, 68.2% reported a statistically significant outcome regarding drug efficacy for chronic peripheral and central NP. Positive studies were cited nearly twice as often as negative studies in the literature (P = 0.01), despite similar study sample size, quality metrics, and publication in journals with similar impact factors. The time to publication, journal impact factor, and conflict of interest did not differ statistically between positive and negative studies. Our observations that negative and positive RCTs were published in journals with similar impact at comparable time-lags after study completion are encouraging. However, the citation bias for positive studies could affect the validity and generalization of conclusions in literature and potentially influence clinical practice.

23 April 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ABAwinita Barpujari
Awinita Barpujari
AKAlina Kiley
Alina Kiley
JRJennifer A. Ross
Jennifer A. Ross
EVErol Veznedaroglu
Erol Veznedaroglu
Chiari Malformation Type I (CM) includes a range of cranial abnormalities at the junction of the skull with the spine, with common symptoms including pain and headaches. Currently, CM pain is managed medically through anti-inflammatory drugs, muscle relaxants, and opioids, while surgical management includes posterior fossa decompression. Given the adverse effects of opioid use, and an ongoing opioid epidemic, there is a need for safe, non-opioid alternatives for clinical pain management. This systematic review was performed to provide an update on the current literature pertaining to the treatment of CM pain with non-opioid alternatives. A literature search was performed in June 2022 utilizing the PubMed and Google Scholar databases, and articles were identified that included information regarding non-opioid pain management in CM patients. A total of 90 articles were obtained from this search, including 10 relevant, drug-specific studies. Two independent reviewers selected and included all relevant articles based on the chosen search criteria to minimize bias risk. Currently available treatments for neurosurgical pain management include anticonvulsants, corticosteroids, NSAIDs, anti-inflammatory drugs, NMDA receptor antagonists, local anesthetics, nerve blocks, scalp blocks, and neuromuscular blocks. While more information is needed on the use of non-opioid pain management, the present literature provides potential evidence of its efficacy amongst the CM patient population, on account of the success that non-opioid pain management has demonstrated within other neurological pain syndromes. Further research into non-pharmacological pain management would also benefit the CM population and could be generalized to related conditions.